The annual open enrollment period for insurance plans is underway from November 1st until December 15th. It is very important to review your health insurance plan before you renew. There are changes…
Read More
An initial lab study has shown metformin, a common diabetes drug, can repair nerve damage caused by MS; Researchers plan to conduct human trial next year. Recently, results from animal…
MS symptoms may create workplace challenges or even prevent work entirely. This webinar is a brief overview of the primary legal tools for staying in the workforce, and suggestions for…
The MS Young Professionals Network (MSYPN) is building community by volunteering and participating at special events, monthly MSYPN meetings, and now through the creation of a mentorship program connecting MSYPN members…
Dr. John Corboy, Co-Director of the Rocky Mountain MS Center at University of Colorado, has been named the inaugural Charles Elliot Morris Chair in Neurology. Dr. Corboy serves as Co-Director…
A recently adopted state law allows for the expanded use of home-based telehealth services in Colorado. Our partners at the Rocky Mountain MS Center at University of Colorado are in…
Pick Your Summit and Hit the Trails in Support of the RMMSC The 2019 MS4MS campaign is in full swing, and we hope you’ll join us on the trails this…
MS doesn’t mean losing your mind. Whether you are newly diagnosed or an experienced person with MS, understanding your changing cognitive challenges leads to identifying coping skills. Join the RMMSC and author…
The Rocky Mountain MS Center’s 2019 Spring Education Summit was held Saturday, April 13 at the Anschutz Medical Campus in Aurora. Below is a recap of the entire Summit, including…
The US Food and Drug Administration (FDA) has approved oral cladribine (brand named Mavenclad®, EMD Serono) for the treatment of adults with relapsing forms of MS, including relapsing-remitting MS and…